Multi-Division PCD Pharma Franchise · WHO-GMP Certified · Telephone: +91 97658 93730 · Submit Application
Aminoglycoside Antibiotic · Critical Care

FRILKACIN-250

Amikacin Sulphate 250mg Injection

Aminoglycoside antibiotic for serious gram-negative infections including those resistant to gentamicin and tobramycin.

Enquire / Get Quote   WhatsApp Enquiry

FRILKACIN 250 by Biofril Healthcare — WHO-GMP manufactured
At a Glance

Product Specifications

Brand NameFRILKACIN-250
Generic / CompositionAmikacin Sulphate IP equivalent to Amikacin 250mg
Therapeutic CategoryAminoglycoside Antibiotic
Dosage FormSolution for injection
Strength250mg/2ml
Route of AdministrationIntramuscular / Slow Intravenous
Pack Size2ml Ampoule/Vial
StorageStore below 25°C. Protect from light.
ManufacturerBiofril Healthcare Pvt. Ltd. · WHO-GMP Plant, Nalagarh HP
Prescription StatusRx — To be sold by retail on the prescription of a Registered Medical Practitioner
Clinical Use

Indications & Clinical Applications

FRILKACIN-250 is indicated for the short-term treatment of serious infections caused by susceptible gram-negative bacteria.

  • Severe gram-negative septicaemia
  • Lower respiratory tract infections caused by Pseudomonas, Klebsiella, E. coli
  • Complicated urinary tract infections
  • Intra-abdominal infections (adjunct)
  • Skin, bone, and soft tissue infections
  • Endocarditis (combination therapy)
Why Biofril FRILKACIN-250

Product Features

  • Effective against gentamicin-resistant strains
  • Suitable for combination therapy
  • WHO-GMP manufactured
  • Hospital and ICU formulary friendly
Safety Information

Warnings & Precautions

Monitor renal function and serum levels (peak/trough). Risk of nephrotoxicity, ototoxicity, neuromuscular blockade. Avoid concurrent nephrotoxic or ototoxic drugs. Adjust dose in renal impairment. Use minimum effective duration.

This information is intended for healthcare professionals only. Always consult the complete product insert and a registered medical practitioner before prescribing or using. Biofril Healthcare is committed to pharmacovigilance — please report any adverse events to biofrilhealthcare@gmail.com.

Enquire About FRILKACIN-250

PCD franchise · Hospital tenders · Bulk supply · Distribution opportunities

Get Quote & Net Rate   Call +91 97658 93730   WhatsApp

← Back to Critical Care Range  |  Critical Care PCD Franchise →